Gilead Sciences Inc. aims to launch Sovaldi, the hepatitis C drug, in India by June and to expand the reach of a generic licensing agreement with Indian drug-makers to include an investigational combination pill. The pill could treat six genotypes of hepatitis C if approved by regulators and is a combination of sofosbuvir, the chemical name for Sovaldi, with GS-5816, a compound in advanced clinical trials in the U.S. Gregg Alton, an executive vice ...
Read More
You have just read an article categorized health
titled Drug for Hepatitis C to be Launched in India by Gilead Sciences.
Written by:
editor -
Monday, January 26, 2015
There are currently no comments for "Drug for Hepatitis C to be Launched in India by Gilead Sciences"
Post a Comment